We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Omega-3 Fatty Acids Block Macrophage Inflammatory Action

By HospiMedica International staff writers
Posted on 13 Sep 2010
A possible dietary approach for ameliorating the symptoms of diabetes is based on omega-3 fatty acids, which recently have been shown to activate a critical inflammation suppressing signaling pathway.

Investigators at the University of California, San Diego (USA) worked with cells growing in culture and with a line of genetically engineered mice to study the relationship between omega-3 fatty acids and the G-protein receptor, GPR120. More...
GPR120, which is limited to fat tissue and macrophages, is a member of a large protein family many of whose members are drug targets.

The investigators reported in the September 3, 2010, issue of the journal Cell that the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) bind to and activate GPR120. Activated GPR120 triggers a molecular pathway that blocks the macrophages' inflammatory role.

They fed obese mice and mice genetically engineered to lack the gene for GPR120 (GPR120 knockout mice) a high fat diet with or without omega-3 fatty acid supplementation. The omega-3 treatment inhibited inflammation and enhanced systemic insulin sensitivity in the obese mice, but was without effect in GPR120 knockout mice.

"It is just an incredibly potent effect,” said senior author Dr. Jerrol Olefsky, professor of medicine at the University of California, San Diego. "The omega-3 fatty acids switch on the receptor, killing the inflammatory response. The receptor evolved to respond to a natural product – omega-3 fatty acids – so that the inflammatory process can be controlled. Our work shows how fish oils safely do this, and suggests a possible way to treating the serious problems of inflammation in obesity and in conditions like diabetes, cancer, and cardiovascular disease through simple dietary supplementation.”

Related Links:
University of California, San Diego


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.